252 related articles for article (PubMed ID: 3668254)
1. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen.
Nores GA; Dohi T; Taniguchi M; Hakomori S
J Immunol; 1987 Nov; 139(9):3171-6. PubMed ID: 3668254
[TBL] [Abstract][Full Text] [Related]
2. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.
Dohi T; Nores G; Hakomori S
Cancer Res; 1988 Oct; 48(20):5680-5. PubMed ID: 3167827
[TBL] [Abstract][Full Text] [Related]
3. Analysis of melanoma antigen and its involvement in tumor-escape mechanisms.
Taniguchi M; Sakatsume M; Harada Y; Nores GA; Hakomori S
Princess Takamatsu Symp; 1988; 19():247-54. PubMed ID: 2978619
[TBL] [Abstract][Full Text] [Related]
4. [GM3 ganglioside as melanoma specific antigen and its biological function].
Hirabayashi Y; Taniguchi M
Hum Cell; 1989 Mar; 2(1):63-9. PubMed ID: 2535260
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
6. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
Gabri MR; Ripoll GV; Alonso DF; Gómez DE
J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
[TBL] [Abstract][Full Text] [Related]
7. Mouse melanoma antigen recognized by Lyt-2- and L3T4- cytotoxic T-lymphocytes.
Ono K; Takahashi K; Hirabayashi Y; Itoh T; Hiraga Y; Taniguchi M
Cancer Res; 1988 May; 48(10):2730-3. PubMed ID: 2452012
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
Ravindranath MH; Brazeau SM; Morton DL
Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
[TBL] [Abstract][Full Text] [Related]
9. Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma.
Hirabayashi Y; Hamaoka A; Matsumoto M; Matsubara T; Tagawa M; Wakabayashi S; Taniguchi M
J Biol Chem; 1985 Oct; 260(24):13328-33. PubMed ID: 2414279
[TBL] [Abstract][Full Text] [Related]
10. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.
Hoon DS; Wang Y; Sze L; Kanda H; Watanabe T; Morrison SL; Morton DL; Irie RF
Cancer Res; 1993 Nov; 53(21):5244-50. PubMed ID: 7916649
[TBL] [Abstract][Full Text] [Related]
11. Cell density regulates crypticity of GM3 ganglioside on human glioma cells.
Tatewaki K; Yamaki T; Maeda Y; Tobioka H; Piao H; Yu H; Ibayashi Y; Sawada N; Hashi K
Exp Cell Res; 1997 May; 233(1):145-54. PubMed ID: 9184084
[TBL] [Abstract][Full Text] [Related]
12. Escape mechanisms of melanoma from immune system by soluble melanoma antigen.
Takahashi K; Ono K; Hirabayashi Y; Taniguchi M
J Immunol; 1988 May; 140(9):3244-8. PubMed ID: 2452202
[TBL] [Abstract][Full Text] [Related]
13. The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process.
Furukawa K; Thampoe IJ; Yamaguchi H; Lloyd KO
J Immunol; 1989 Feb; 142(3):848-54. PubMed ID: 2464027
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity of leukemic lymphoblasts of T-cell and B-cell precursor origin with monoclonal anti-GD3 and anti-GM3 antibodies.
Merritt WD; Sztein MB; Taylor B; Reaman GH
Leukemia; 1991 Dec; 5(12):1087-91. PubMed ID: 1774957
[TBL] [Abstract][Full Text] [Related]
15. Induction of mouse anti-melanoma cytotoxic and suppressor T cells in vitro by an artificial antigen, GM3-lactone.
Harada Y; Sakatsume M; Taniguchi M
Jpn J Cancer Res; 1990 Apr; 81(4):383-7. PubMed ID: 2142151
[TBL] [Abstract][Full Text] [Related]
16. Density of GM3 with normal primary structure determines mouse melanoma antigenicity; a new concept of tumor antigen.
Harada Y; Sakatsume M; Nores GA; Hakomori S; Taniguchi M
Jpn J Cancer Res; 1989 Oct; 80(10):988-92. PubMed ID: 2533193
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
18. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
[TBL] [Abstract][Full Text] [Related]
19. Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells.
Inokuchi J; Momosaki K; Shimeno H; Nagamatsu A; Radin NS
J Cell Physiol; 1989 Dec; 141(3):573-83. PubMed ID: 2531751
[TBL] [Abstract][Full Text] [Related]
20. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
